In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MetaXen LLC

Division of Exelixis Inc.

Latest From MetaXen LLC

Selected Start-Ups Founded in 2000 (0002)

{In Vivo} summarizes the technologies of several medical companies founded recently, including Belgium's [AlgoNomics NV], a new entrant in the biocomputing and bioinformatics arena. [CoPharma Inc.]'s mission is to develop drug and biological products through joint ventures with discovery firms. Launched in February 2000 with $2 million from Sanderling, Alta Partners and Graystone, [Cythera Inc.] will develop therapies based on the transplantation of functional human cells grown{ in vitro}, offering an alternative to the use of donated human tissues. [Embolic Protection Inc.] has developed a device, consisting of a guide wire and filter mechanism, to remove embolic debris. Denmark's [NsGene A/S] is a joint venture of NeuroSearch A/S and the University of Lund. [WebEBM] will offer evidence-based clinical guidelines for 400 diseases or conditions on its website.

Market Pressure, Part I: Biotechs Feel the Chill

Dismal conditions in the public capital markets can't help but affect biotech start-ups too. Venture capitalists are reassessing operating and exit strategies, and contemplating new business models.
BioPharmaceutical Strategy

Re-Engineering Drug Development I: Simulating Clinical Trials

As the cost and complexity of clinical drug development increases, start-ups are creating new technologies to speed things along. In Part I of our survey, we look at companies adapting computer simulation techniques from industries like aerospace to develop and design clinical trials. The two top simulation companies are thrashing out strategies as they debate adopting product or service business models.
BioPharmaceutical Business Strategies

Drug Development's Preclinical Bottleneck

Thanks to genomics, combinatorial chemistry, and high-throughput screening, pharmaceutical companies have more drug leads than ever. But which are the drugs? Start-up firms with faster, smarter approaches to preclinical testing may help sort out the answers. Information technology will play a key role in lead optimization as new firms with simulation software are helping drug developers plot development strategies earlier than ever.
BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Exelixis Inc.
  • Senior Management
  • Michael J Ross, PhD, Pres. & CEO
    Dr. Lutz Giebel, VP, Res.
    David Matthews, PhD, Principal Scientist
  • Contact Info
  • MetaXen LLC
    Phone: (650) 553-8100
    280E. Grand avenue
    So.San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register